Speaker Innovation for Health 2023

Eric van der Putten | Director, Modra Pharmaceuticals

Eric 30 started his career in 1983 as head trial department Comprehensive Cancer Center. Between 1990 and 2007 he held several positions at companies specialized in clinical research including NDDO Oncology, where he acted as COO and CEO. After INC Research acquired NDDO Oncology in 2005, Eric became Vice President of Oncology for Europe of INC Research. Eric is co-founder of SMS-oncology, a specialized oncology CRO established in 2007 where he worked as COO and CEO. In 2013 he became a partner at Aglaia Oncology Funds. Furthermore, Eric is a director at Modra Pharmaceuticals and a non-executive director at Mimetas.

Modra Pharmaceuticals

Modra was founded in June 2010 as a spin-out of the Netherlands Cancer Institute and is based in Amsterdam, Netherlands. “Modra” stands for “Modulated Oral Drug Absorption” and for our commitment to transforming taxane therapy, by developing improved therapies that are safer, better tolerated, and can be conveniently taken at home in tablet form. We are applying our proprietary platform to develop next-generation oral taxanes with the goal to improve the therapeutic outcomes and everyday lives of cancer patients undergoing taxane therapy. Our lead program is ModraDoc006/r, a boosted oral formulation of docetaxel.

Powered by:
Hyphen Projects

Let's connect:

Book a ticket

FAQ
Contact Us
Privacy Policy
Terms & Conditions
Chamber of Commerce: 32110979
VAT no: NL8184.34.491.B01

Keep me informed Download our event app

© Copyright 2023 by Hyphen Projects